Use of Molecular Imaging to Differentiate Liver Metastasis of Colorectal Cancer Metastasis From Neuroendocrine Tumor Origin

Journal of Clinical Gastroenterology

Volumn 45, Issue 1, 2011, Pages e8-e11

  Desai, Kiran ^a   Watkins, Jennifer ^a   Woodward, Nicholas ^b   Quigley, Anne Marie ^b   Toumpanakis, Christos ^b   Bomanji, Jamshed ^b   Caplin, Martyn ^b  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Carcinoid; Colon cancer; Colorectal cancer; Metachronous malignancy; Net; Neuroendocrine tumor; Synchronous malignancy

Indexed keywords

CAPECITABINE; FLUORODEOXYGLUCOSE F 18; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHRONIC PANCREATITIS; COLON ADENOCARCINOMA; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER METASTASIS; MALE; MITOSIS; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WEIGHT REDUCTION;

BIOPSY; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 78650936895     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181e04d3c     Document Type: Article

References (20)

1. Meckel JF. Uber die Divertikel am darmkanal. Arch Die Physio. 1809;9:421-453
2. Pearson CM, Fitzgerald PJ. Carcinoid tumours: a re-emphasis of their malignant nature: review of 140 cases. Cancer. 1949;2:1005-1026
3. Goodwin JD. Carcinoid tumors: an analysis of 2837 cases. Cancer. 1975;36:560-569
4. Feldman JM. Carcinoid tumors and the carcinoid syndrome. Current Problems Surgery. 1989;26:831-885
5. Gerstle JT, Kauffman GL Jr, Koltun WA. The incidence, management, and the outcome of patients with gastrointestinal carcinoids and second primary malignancies. J Am Coll Surgery. 1995;180:427-432
6. 18F-FDG. Cancer. 2008;112:2447-2455
7. Tetzlaff ED, Ajani JA. Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. Int J Gastrointest Cancer. 2005;36:55-58
8. Díaz-Rubio E, Tabernero J, Gómez-España A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the treatment of digestive tumors trial. J Clin Oncol. 2007;25:4224-4230
9. Maddams J, Moller H, Devane C. Cancer Prevalence in the UK 2008 National Cancer Intelligence Network Coordinating Centre Thames Cancer Registry and Macmillan Cancer Support
10. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072
11. Modlin I, Lye KD, Kidd M. A 5-Decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959
12. Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Nat Acad Sci. 1977;74:3735
13. Eriksson B, Bergström M, Sundin A, et al. The role of PET in localization of neuroendocrine and adrenocortical tumors. Annals N Y Acad Sci. 2002;970:159-169
14. Eriksson B, Bergström M, Orlefors H, et al. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med. 2000;44:68-76
15. Kwekkeboom DJ, Kooij PP, Bakker WH, et al. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumour uptake. J Nucl Med. 1999;40:762-767
16. Schonbrunn A. Somatostatin receptors present knowledge and future directions. Ann Oncol. 1999;10(suppl 2):S17-S21
17. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin tracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282
18. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumours. Semin Nucl Med. 2006;36:228-247
19. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518
20. Veit P, Kühle C, Beyer T, et al. Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut. 2006;55:68-73